Another US Stelara Settlement Arrives, This Time For Fresenius And Formycon

Deal With Johnson & Johnson Allows US Biosimilar Ustekinumab Entry In 2025

A third settlement has been struck allowing a Stelara biosimilar to hit the US market in 2025, with partners Fresenius and Formycon agreeing terms with Johnson & Johnson that offer a launch date slightly later than previous settlers.

Red jigsaw pieces spelling out '2025'
The pieces are starting to fall into place for a series of ustekinumab biosimilar launches in the US in 2025 • Source: Shutterstock

With news of a third settlement over a proposed Stelara (ustekinumab) biosimilar in the US, a pattern seems to be emerging: the earlier you settle with Johnson & Johnson, the earlier your rival to Stelara can hit the market.

Fresenius Kabi and Formycon have just announced a settlement over their partnered FYB202 candidate with the originator, with...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Deals

More from Business